INDIANAPOLIS — Indiana University School of Medicine has named Bryan P. Schneider, MD, the associate dean for clinical trials.
In this strategic leadership role, Schneider will collaborate closely with faculty across IU School of Medicine, IU Health and the IU Launch Accelerator for Biosciences (IU-LAB) to drive prioritization, startup and patient enrollment, with an initial focus on Eli Lilly and Co.-sponsored clinical trials.
“Dr. Schneider brings a rare combination of clinical expertise, research innovation and proven leadership to this new role,” said Jay L. Hess, MD, PhD, MHSA, executive vice president for university clinical affairs at IU and dean of the IU School of Medicine. “His work has consistently advanced precision oncology and removed barriers to clinical trial participation. This new role will allow him to build on that record to strengthen and expand our clinical research enterprise.”
Schneider, the Vera Bradley Professor of Oncology and a professor of medicine and medical and molecular genetics at the IU School of Medicine, is a distinguished medical oncologist specializing in breast cancer and precision genomics. He is the founding director of the IU Health Precision Genomics Program, which has performed next-generation sequencing on more than 10,000 advanced cancer patients and serves as a model for precision medicine programs nationwide.
“Clinical trials are vehicles through which discovery becomes care,” said Schneider, who is also a member of the IU Melvin and Bren Simon Comprehensive Cancer Center. “I look forward to strengthening the infrastructure and partnerships that allow us to more swiftly and equitably translate advances into improved outcomes for patients.”
In this role, Schneider will coordinate with IU-LAB leadership to serve as the IU School of Medicine lead for Lilly-sponsored trials, function as a central liaison with the Clinical Trials Office at the IU Simon Comprehensive Cancer Center, and work to monitor key performance indicators essential to enhancing the school’s clinical trial enterprise.
Tatiana Foroud, PhD, executive associate dean for research affairs at IU School of Medicine, said Schneider’s leadership will be instrumental in advancing the school’s research goals.
“Dr. Schneider’s vision and experience exemplify the translational research strengths at IU School of Medicine,” Foroud said. “His focus on equitable, precision-driven clinical innovation aligns with our mission to serve all communities through rigorous research.”
About the Indiana University School of Medicine
The IU School of Medicine is the largest medical school in the U.S. and is annually ranked among the top medical schools in the nation by U.S. News & World Report. The school offers high-quality medical education, access to leading medical research and rich campus life in nine Indiana cities, including rural and urban locations consistently recognized for livability. According to the Blue Ridge Institute for Medical Research, the IU School of Medicine ranks No. 13 in 2024 National Institutes of Health funding among all public medical schools in the country.
Writer: Katie Duffey, kaduffey@iu.edu
For more news, visit the IU School of Medicine Newsroom: medicine.iu.edu/news